Research programme: platinum-based anticancer therapeutics - CTI BioPharma
Alternative Names: BBR 3610; CT-3610; CT-47463; CT-47609; CT-47613Latest Information Update: 28 Jun 2023
At a glance
- Originator Roche; University of Vermont
- Developer CTI BioPharma
- Class Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Jun 2023 CTI BioPharma has been acquired by Swedish Orphan Biovitrum
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 30 May 2014 Cell Therapeutics is now called CTI BioPharma